Patents by Inventor Richard N. Kolesnick

Richard N. Kolesnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10722577
    Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 28, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
  • Publication number: 20190046538
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 14, 2019
    Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas System
    Inventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
  • Publication number: 20180015184
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 18, 2018
    Inventors: Richard N. Kolesnick, Branka Stancevic, Michel Sadelain, Zvi Fuks, Nira Varda-Bloom, Dror Harats
  • Publication number: 20180015183
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: July 6, 2017
    Publication date: January 18, 2018
    Applicants: MEMORIAL SLOANE-KETTERING CANCER CENTER, Vascular Biogenics Ltd.
    Inventors: Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
  • Publication number: 20170273987
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: February 20, 2017
    Publication date: September 28, 2017
    Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas System
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 9592238
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 14, 2017
    Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Publication number: 20170007718
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: September 4, 2015
    Publication date: January 12, 2017
    Inventors: Richard N. Kolesnick, Branka Stancevic, Michel Sadelain, Zvi Fuks, Nira Varda-Bloom, Dror Harats
  • Publication number: 20150216971
    Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, CGvHD disease, inflammatory diseases and autoimmune diseases.
    Type: Application
    Filed: May 29, 2013
    Publication date: August 6, 2015
    Applicant: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
  • Publication number: 20140205543
    Abstract: The invention provides compositions and methods for diagnosing tumors and augmentic therapeutic intervention and measuring response to cell stress using sphingomyelin containing liposomes. The liposomes can include radiotracers, contrast agents, chromophores, dyes, enzyme substrates, therapeutic agents, chemotherapeutic agents or DNA segments. The indicators enable measurement of the extent of cellular release of Acid SMase at a localized site of cell stress. The nanoparticles have the capacity to locally release their contents, be it imaging (for diagnosis) or therapeutic agents (to augment therapy).
    Type: Application
    Filed: January 23, 2014
    Publication date: July 24, 2014
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Oula Penate-Medina, Tuula Penate-Medina, Steven M. Larson, Jan Grimm, Daniel L.J. Thorek, Richard N. Kolesnick
  • Publication number: 20140112932
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 24, 2014
    Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 8283459
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: October 9, 2012
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Publication number: 20120252883
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: December 7, 2010
    Publication date: October 4, 2012
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER ("MSKCC")
    Inventors: Richard N. Kolesnick, Branka Stancevic, Michel Sadelain, Zvi Fuks, Nira Varda-Bloom, Dror Harats
  • Patent number: 8258108
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: September 4, 2012
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 7850984
    Abstract: Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: December 14, 2010
    Assignees: The General Hospital Corporation, Memorial Sloan-Kettering Cancer Center
    Inventors: Jonathan L. Tilly, Richard N. Kolesnick
  • Publication number: 20090143320
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Application
    Filed: October 12, 2007
    Publication date: June 4, 2009
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 7528116
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: May 5, 2009
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 7301017
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gƒ Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: November 27, 2007
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 7195775
    Abstract: Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: March 27, 2007
    Assignee: The General Hospital Corporation
    Inventors: Jonathan L. Tilly, Richard N. Kolesnick
  • Publication number: 20030157086
    Abstract: Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.
    Type: Application
    Filed: August 12, 2002
    Publication date: August 21, 2003
    Inventors: Jonathan L. Tilly, Richard N. Kolesnick
  • Patent number: 6040149
    Abstract: The subject invention provides a purified membrane-bound ceramide-activated protein kinase having an apparent molecular weight of about 110 kD as determined by SDS polyacrylamide gel electrophoresis, which protein kinase is capable of specifically phosphorylating the threonine residue in a Thr-Pro- or a Thr-Leu-Pro-containing polypeptide. The subject invention also provides a method of determining whether an agent is capable of specifically inhibiting the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of determining whether an agent is capable of specifically stimulating the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of treating a subject having an inflammatory disorder. The subject invention further provides a method of treating a human subject infected with HIV so as to reduce the proliferation of HIV in the human subject.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 21, 2000
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard N. Kolesnick, Jun Liu, Yuhua Zhang